Curative treatments in oligometastatic MSK disease – online course
Authors: J. Garnon and D. Filippiadis
Reviewers: F. Deschamps, M. Hoffmann, T. Jahnke, G. Mauri, C. Nice, R. Uberoi
This course corresponds to chapter 220.127.116.11 Percutaneous Ablation of Bone and Soft Tissue Lesions in the European Curriculum and Syllabus for IR.
Metastatic bone disease is most commonly seen with specific cancer types, including those arising from breast, prostate, lung and kidney, whilst multiple myeloma seems to be the most common of hematologic malignancies. New systemic treatments may render a wider range of patients prone to becoming oligometastatic; in these patients, local therapies combined to systemic therapies are likely to play an important role in the oncologic management. Percutaneous thermal ablation by means of radiofrequency, cryoablation or microwave energy can be used as a curative therapy in oligometastatic musculoskeletal disease aiming to achieve local tumour control. According NCCN guidelines, ablation for adult cancer pain can be proposed when there is no oncologic emergency (e.g. pathologic fracture or epidural disease) or when the pharmacologic therapy is inadequate and radiation therapy is contraindicated or not desired by the patient. During thermal ablation, irreversible thermal damage and coagulation necrosis is achieved by energy application. A treatment algorithm is necessary for the indication of ablation in bone metastases and for combining ablation to bone augmentation in weight bearing locations and long bones.
- Define the actual indications and limits of focal tumour control
- Describe the treatments used and how to choose them
- Describe the patient pathway and collaboration with other specialists and the patient follow up
This course covers a basic level of IR knowledge and is designed for trainees, students or young consultants aiming to acquire essential knowledge or prepare for the EBIR exam. Thereby, it is tailored to the European Curriculum and Syllabus for IR and corresponds to chapter 18.104.22.168 Percutaneous Ablation of Bone and Soft Tissue Lesions.
The format of the course is easy to use and interactive by including texts, graphics, videos and a quiz to support your learning. The course duration is around one hour and is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to award 1 European CME credit (ECMEC).
Upon purchase, access to complete and revisit the course is granted for an enrolment period of 90 days. The certificate of completion will be available beyond the enrolment period in the new myCIRSE area.
Release date: January 2020
This course is available until January 3, 2022.